Anticipated shortage
Novartis/Genentech global demand surge for omalizumab across severe asthma and chronic urticaria. Australian allocation under review.
Expected resolution: 31 December 2025
omalizumab
Xolair
150 mg/mL · injection · Severe Asthma
PBS Pricing
| General patient co-payment | $31.60 |
| Concession co-payment | $7.70 |
| Full dispensed price | $848.00 |
PBS Information
- Item code
- RESx10
- Drug name
- omalizumab
- Brand name
- Xolair
- Manufacturer
- Novartis
- Formulation
- injection
- Strength
- 150 mg/mL
- Max quantity
- 2 units
- Max repeats
- 5
- PBS listed
- Yes
- Therapeutic group
- Severe Asthma
TGA Reference: TGA-MSI-2025-045 · Sponsor: Novartis Pharmaceuticals Australia Pty Ltd
MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.